SC
LVTX

Steven Cohen’s LAVA Therapeutics LVTX Stock Holding History

Steven Cohen’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-111,993
Closed -$330K – 1596
2022
Q2 		$330K Sell
111,993
-4,988
-4% -$17.3K ﹤0.01% 1235
2022
Q1 		$515K Sell
116,981
-2,171
-2% -$11K ﹤0.01% 1013
2021
Q4 		$655K Sell
119,152
-4,759
-4% -$31.2K ﹤0.01% 947
2021
Q3 		$734K Buy
+123,911
New +$892K ﹤0.01% 893
2021
Q2 		– Sell
-5,561
Closed -$84K – 1084
2021
Q1 		$84K Buy
+5,561
New +$76.4K ﹤0.01% 909

Other funds holding LVTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $149M AUM 39.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steven Cohen's LVTX Position: Q3 2022 in Review

Steven Cohen sold out of LAVA Therapeutics (LVTX) in Q3 2022, closing a stake of 111,993 shares — an estimated $330K sold.

Steven Cohen first reported a position in LVTX in Q1 2021 and held it in 5 quarters. The position peaked at $734K in Q3 2021. 13 funds tracked by Wall St. Rank hold LVTX as of Q3 2022.

  • Steven Cohen reported no remaining LAVA Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Steven Cohen sold 111,993 LAVA Therapeutics shares in Q3 2022, an estimated $330K.
  • Steven Cohen first reported a position in LAVA Therapeutics in Q1 2021 and held it in 5 quarters.
  • Steven Cohen's LAVA Therapeutics position peaked at $734K in Q3 2021.
  • 13 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q3 2022.

Based on Point72 Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.